Additional file 2 of Evaluation of the cost-effectiveness of dexrazoxane for the prevention of anthracycline-related cardiotoxicity in children with sarcoma and haematologic malignancies: a European perspective

Additional file 2. Relative risks for clinical cardiotoxicity and subclinical toxicity. Table showing the relative risk data for clinical cardiotoxicity and subclinical cardiotoxicity based on standardised mortality ratio evidence only or based on non-randomised, double-arm interventional studies.